GeoVax Labs (GOVX) Q1 2026 earnings summary

Executive summary

• GEO-MVA (mpox/smallpox vaccine) is advancing toward a pivotal Phase 3 trial under an expedited EMA-aligned regulatory pathway, targeting global supply constraints.

• Gedeptin immuno-oncology platform is expanding through combination strategies with checkpoint inhibitors and an exclusive license with Emory University, with Phase 2 trials planned.

• GEO-CM04S1 (COVID-19 vaccine) remains in multiple Phase 2 studies for immunocompromised and CLL patients.

• Strategic prioritization and capital allocation are focused on GEO-MVA and Gedeptin, aligning with regulatory and commercial opportunities.

• No product revenue generated to date; operations funded primarily through equity offerings and government contracts.

Financial highlights

• No revenue reported for Q1 2026 due to BARDA contract termination; Q1 2025 revenue was $1.64 million.

• Research and development expenses decreased to $3.9 million, down 27% year-over-year, mainly from lower costs after BARDA contract termination.

• General and administrative expenses fell to $1.37 million, reflecting reduced consulting and stock-based compensation.

• Net loss for Q1 2026 was $5.3 million, compared to $5.4 million in Q1 2025.

• Cash and cash equivalents were $1.3 million as of March 31, 2026, down from $3.1 million at year-end 2025.

Outlook and guidance

• Existing cash resources are expected to fund operations into June 2026; substantial additional funding will be required for continued development and operations.

• Phase 3 immunobridging study for GEO-MVA expected to enroll approximately 500 participants, aiming for rapid clinical validation and regulatory submission.

• Management is seeking further capital through equity, debt, grants, or partnerships but notes substantial doubt about the ability to continue as a going concern.

• Continued focus on expanding Gedeptin into combination immunotherapy strategies and broader solid tumor indications.

• Ongoing evaluation of strategic partnerships and funding opportunities to support development priorities.